Orogen Therapeutics
Orogen Therapeutics is pioneering a novel drug discovery approach that integrates proprietary focused DNA-encoded libraries (Focus DEL™), virtual screening, and bespoke chemical adaptation, powered by machine learning. The company aims to deliver groundbreaking clinical solutions to patients with serious unmet medical needs, focusing on key targets for inflammatory and immune diseases. With a team of veteran scientists and a commitment to innovative technologies, Orogen is positioned to efficiently derive novel drug candidates in less time and at lower costs, making significant strides in the small-molecule drug discovery paradigm.
Orogen Therapeutics
Orogen Therapeutics is pioneering a novel drug discovery approach that integrates proprietary focused DNA-encoded libraries (Focus DEL™), virtual screening, and bespoke chemical adaptation, powered by machine learning. The company aims to deliver groundbreaking clinical solutions to patients with serious unmet medical needs, focusing on key targets for inflammatory and immune diseases. With a team of veteran scientists and a commitment to innovative technologies, Orogen is positioned to efficiently derive novel drug candidates in less time and at lower costs, making significant strides in the small-molecule drug discovery paradigm.
TL;DR
Location: Woburn, Massachusetts
Founded: 2023
Tech focus: AI-enabled DNA-encoded library (FocusDEL) for small-molecule discovery
Therapeutic area: Immuno-inflammatory / cytokine targets
Funding: Series A (Jun 21, 2023); investors: Novalis, Anterra Capital
Employees (approx.): 18
Company Overview
Problem Domain
Discovery of oral small-molecule therapeutics targeting cytokines and immuno-inflammatory diseases.
Founded
2023
Industry
Biotechnology
Tech Stack
Funding Track Record
Investors reported: Novalis, Anterra Capital